Patient-delivered partner therapy: One option for management of sexual partner(s) of a patient diagnosed with a chlamydia infection

Coombe, Jacqueline; Goller, Jane L; Bittleston, Helen; Bateson, Deborah; Bourne, Christopher; O’Donnell, Heather; Tomnay, Jane; Temple-Smith, Meredith; Hocking, Jane

doi:10.31128/ajgp-07-21-6066

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDPT article 39 that provides an overview of the process of offering PDPT and addresses the challenges GPs may face in its provision.…”

Section: Methodsmentioning

confidence: 99%

“…Our pilot results informed further modifications to the website for evaluation in this trial (www.mocca.org.au/about-mocca/research-outputs). Other resources include flow charts, patient fact sheets (developed with health consumer input), mailed specimen kits, autofills for streamlining documentation of the chlamydia consultation and published educational articles outlining best practice chlamydia management,37–39 including our PID article in which clinicians can take the associated quiz to contribute to their continuing professional development requirements. A link to the website can be bookmarked within the EMR or search engine allowing easy access during a consultation.…”

Section: Methodsmentioning

confidence: 99%

“…► PDPT article39 that provides an overview of the process of offering PDPT and addresses the challenges GPs may face in its provision. ► Chlamydia management article38 outlines best practice to reduce chlamydia-associated reproductive complications in women, including partner management.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

IntroductionThe sexually transmitted infection chlamydia can cause significant complications, particularly among people with female reproductive organs. Optimal management includes timely and appropriate treatment, notifying and treating sexual partners, timely retesting for reinfection and detecting complications including pelvic inflammatory disease (PID). In Australia, mainstream primary care (general practice) is where most chlamydia infections are diagnosed, making it a key setting for optimising chlamydia management. High reinfection and low retesting rates suggest partner notification and retesting are not uniformly provided. The Management of Chlamydia Cases in Australia (MoCCA) study seeks to address gaps in chlamydia management in Australian general practice through implementing interventions shown to improve chlamydia management in specialist services. MoCCA will focus on improving retesting, partner management (including patient-delivered partner therapy) and PID diagnosis.Methods and analysisMoCCA is a non-randomised implementation and feasibility trial aiming to determine how best to implement interventions to support general practice in delivering best practice chlamydia management. Our method is guided by the Consolidated Framework for Implementation Research and the Normalisation Process Theory. MoCCA interventions include a website, flow charts, fact sheets, mailed specimen kits and autofills to streamline chlamydia consultation documentation. We aim to recruit 20 general practices across three Australian states (Victoria, New South Wales, Queensland) through which we will implement the interventions over 12–18 months. Mixed methods involving qualitative and quantitative data collection and analyses (observation, interviews, surveys) from staff and patients will be undertaken to explore our intervention implementation, acceptability and uptake. Deidentified general practice and laboratory data will be used to measure pre-post chlamydia testing, retesting, reinfection and PID rates, and to estimate MoCCA intervention costs. Our findings will guide scale-up plans for Australian general practice.Ethics and disseminationEthics approval was obtained from The University of Melbourne Human Research Ethics Committee (Ethics ID: 22665). Findings will be disseminated via conference presentations, peer-reviewed publications and study reports.

show abstract

“…PDPT article 39 that provides an overview of the process of offering PDPT and addresses the challenges GPs may face in its provision.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“… 18 GPs are well placed to provide guidance for patients when engaging in partner notification, including through the use of anonymous online notification tools. Moreover, patient‐delivered partner therapy is an effective way to both treat the partners and reduce reinfection in the index case 22 , 23 — the Australasian Contact Tracing Guidelines detail the situations where patient‐delivered partner therapy is appropriate. 10…”

Section: Enhance Partner Notification and Managementmentioning

confidence: 99%

Chlamydia prevention and management in Australia: reducing the burden of disease

Munari

Goller

Hellard

et al. 2022

Medical Journal of Australia

Self Cite

View full text Add to dashboard Cite

show abstract

Patient-delivered partner therapy for chlamydia: health practitioner views on updated guidance in Victoria, Australia

Warda,

Bittleston,

Coombe

et al. 2024

Sex. Health

View full text Add to dashboard Cite

Background Patient-delivered partner therapy (PDPT) involves providing a prescription or medication to a patient diagnosed with chlamydia to pass to their sexual partner/s. Barriers to PDPT include uncertainty about its integration into clinical practice and permissibility. In Victoria, Australia, the Department of Health provides clinical guidance for PDPT (updated in 2022). We explored health practitioner views on the usefulness of the updated guidance for providing PDPT. Methods We conducted an online survey (12 December 2022 to 2 May 2023) of health practitioners who primarily work in Victoria and can prescribe to treat chlamydia. The survey displayed excerpts from the guidance, and asked closed and free-text questions about its ability to address barriers to PDPT. Quantitative data were descriptively analysed, complemented by conventional content analysis of qualitative data. Results Of a total of 49 respondents (66.7% general practitioners), 74.5% were aware of PDPT, and 66.7% had previously offered PDPT. After viewing excerpts of the guidance, >80% agreed it could support them to identify patients eligible/ineligible for PDPT, and 66.7% indicated they would be comfortable to offer PDPT. The guidance was viewed as helpful to address some barriers, including complicated documentation (87.7%) and medico-legal concerns (66.7%). Qualitative data highlighted medico-legal concerns by a minority of respondents. Some raised concerns that the guidance recommended prescribing azithromycin, despite doxycycline being first-line chlamydia treatment. Conclusions The guidance was largely viewed as supportive for PDPT decision-making. There is scope for further refinements and clarifications, and wider dissemination of the guidance.

show abstract

Patient-delivered partner therapy: One option for management of sexual partner(s) of a patient diagnosed with a chlamydia infection

Cited by 3 publications

References 10 publications

Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trial

Management of Chlamydia Cases in Australia (MoCCA): protocol for a non-randomised implementation and feasibility trial

Chlamydia prevention and management in Australia: reducing the burden of disease

Patient-delivered partner therapy for chlamydia: health practitioner views on updated guidance in Victoria, Australia

Contact Info

Product

Resources

About